



# PYC Therapeutics

Life-changing science

Investor Webinar Q1 2024

February 2024



# Disclaimer

---



The purpose of this presentation is to provide an update of the business of PYC Therapeutics Limited (ASX:PYC) ['PYC']. These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by PYC Therapeutics and should not be relied upon as an independent source of information. Please contact PYC and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information.

Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other

factors, many of which are outside PYC's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and PYC's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution.

This presentation should not be relied on as a recommendation or forecast by PYC. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.


# PYC Therapeutics

- PYC is a precision medicine company progressing a pipeline of best-in-class drug candidates towards major unmet patient needs
- Each drug candidate represents a significant commercial opportunity
- In 2024, PYC will begin to generate the human safety and efficacy data critical to defining both the patient-impact and commercial success of this pipeline

# PYC has multiple assets progressing towards major unmet patient needs




# PYC's strategy sees it developing best-in-class assets



# PYC's commercial opportunities are significant and the path to revenue generation is clear

Indication	Market size <sup>1</sup>	Commercialisation <sup>2</sup>		
		2028	2029	2030
Retinitis Pigmentosa 11	\$1 billion p.a.	✓	✓	✓
Polycystic Kidney Disease	\$10 billion p.a.		✓	✓
Optic Atrophy	\$2 billion p.a.		✓	✓

# PYC's path to market sees 5 human data read-outs within 36 months



---

Q&A

---

